The neurotransmitter acetylcholine (ACh) acts as an autocrine growth factor for human lung
cancer. Several lines of evidence show that lung cancer cells express all of the proteins …

Lung cancer is the leading cause of cancer-related mortality globally, accounting for 1.8
million deaths in 2020. While the vast majority are caused by tobacco smoking, 15%− 25 …

Purpose In the current targeted therapy era, information on the effect of smoking in
epidermal growth factor receptor (EGFR)-mutant lung cancer patients is scarce. Results In …

Immune checkpoint inhibitors (ICIs) have emerged as a new treatment option for patients
with advanced non-small-cell lung cancer (NSCLC). Some studies with ICIs in NSCLC …

Background A growing number of regimens have been approved as first-line treatments for
patients with advanced epidermal growth factor receptor (EGFR) mutated non-small cell …

Objective This study was designed to demonstrate the prognostic value of prognostic
nutritional index (PNI), a reflection systemic immunonutritional status, on the long-term …

Background Osimertinib is one of the standard first-line treatments for advanced non-small
cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations …

Background A growing body of evidence supports the role of platelets in cancer metastasis,
escape from immune surveillance, and angiogenesis. Mean platelet volume (MPV), which …

Background The relationship between epidermal growth factor receptor (EGFR) gene
mutation status, preoperative computed tomography (CT), and clinical features in patients …

Purpose Large-scale, prospective, randomized studies of the efficacy of thoracic
radiotherapy (RT) in patients with unresectable stage IIIB–IV epidermal growth factor …